z-logo
open-access-imgOpen Access
<p>Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis</p>
Author(s) -
Rhea Singh,
Courtney E Heron,
Rima I. Ghamrawi,
Lindsay C. Strowd,
Steven R. Feldman
Publication year - 2020
Publication title -
immunotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.256
H-Index - 7
ISSN - 2253-1556
DOI - 10.2147/itt.s229667
Subject(s) - janus kinase , medicine , atopic dermatitis , adverse effect , clinical trial , tofacitinib , immunology , dermatology , pharmacology , cytokine , rheumatoid arthritis
Atopic dermatitis (AD) is a common chronic, inflammatory skin condition. The pathogenesis of AD involves many cytokines that utilize the Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling cascade; therefore, JAK inhibitors may be used in the treatment of AD. This review aims to evaluate the pathophysiology, efficacy, and safety of JAK inhibitors and their emerging role as a therapeutic option for patients with AD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here